{"id":544434,"date":"2025-11-19T10:03:12","date_gmt":"2025-11-19T10:03:12","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/544434\/"},"modified":"2025-11-19T10:03:12","modified_gmt":"2025-11-19T10:03:12","slug":"pourquoi-ce-medicament-tres-attendu-risque-de-ne-pas-etre-rembourse-en-france","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/544434\/","title":{"rendered":"pourquoi ce m\u00e9dicament tr\u00e8s attendu risque de ne pas \u00eatre rembours\u00e9 en France"},"content":{"rendered":"

Le lecanemab est un anticorps monoclonal ciblant les plaques amylo\u00efdes, des d\u00e9p\u00f4ts anormaux de prot\u00e9ines qui perturbent la communication entre les cellules c\u00e9r\u00e9brales.
\n ipopba – stock.adobe.com<\/p>\n

\n D\u00c9CRYPTAGE<\/strong> – Dans un avis rendu le 7 novembre, la Haute autorit\u00e9 de Sant\u00e9 s\u2019est prononc\u00e9e contre le remboursement du Leqembi, autoris\u00e9 en Europe depuis avril dernier. Suscitant \u00ab\u00a0l\u2019incompr\u00e9hension\u00a0\u00bb des associations de malades et de m\u00e9decins sp\u00e9cialistes.<\/p>\n

Les malades d\u2019Alzheimer, dont le nombre est estim\u00e9 \u00e0 plus d\u2019un million en France, ont peu d\u2019options th\u00e9rapeutiques m\u00e9dicamenteuses, et aucune prise en charge par la collectivit\u00e9. La commercialisation en 2023 aux \u00c9tats-Unis\u00a0et l\u2019autorisation accord\u00e9e par l\u2019Agence europ\u00e9enne du m\u00e9dicament<\/a>\u00a0\u00e0 un nouveau m\u00e9dicament, le Leqembi, avait donc suscit\u00e9 un grand espoir. Ce traitement, dont la mol\u00e9cule active est le lecanemab, est destin\u00e9 \u00e0 ralentir la progression de la maladie chez des patients diagnostiqu\u00e9s au stade pr\u00e9coce d\u2019Alzheimer et atteints de troubles de la m\u00e9moire l\u00e9gers. Il est autoris\u00e9 en Europe depuis avril dernier.<\/p>\n

Dans un avis rendu le 7 novembre,\u00a0la Haute autorit\u00e9 de Sant\u00e9<\/a>\u00a0s\u2019est pourtant prononc\u00e9e contre son remboursement, suscitant \u00ab\u00a0l\u2019incompr\u00e9hension\u00a0\u00bb des associations de malades et de m\u00e9decins sp\u00e9cialistes. \u00ab\u00a0Apr\u00e8s le d\u00e9remboursement en 2018 des traitements symptomatiques, le message envoy\u00e9 aux patients qui ont une forme d\u00e9butante est vraiment tr\u00e8s n\u00e9gatif\u00a0\u00bb, commente le\u2026<\/p>\n

\n Cet article est r\u00e9serv\u00e9 aux abonn\u00e9s. Il vous reste 85% \u00e0 d\u00e9couvrir.\n <\/p>\n

\"Le<\/p>\n

Black Friday<\/p>\n

-70% sur l’abonnement num\u00e9rique<\/p>\n

\n D\u00e9j\u00e0 abonn\u00e9\u00a0?
\n Connectez-vous
\n <\/a>\n <\/p>\n","protected":false},"excerpt":{"rendered":"Le lecanemab est un anticorps monoclonal ciblant les plaques amylo\u00efdes, des d\u00e9p\u00f4ts anormaux de prot\u00e9ines qui perturbent la…\n","protected":false},"author":2,"featured_media":544435,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[772,1011,27,72,222,71],"class_list":{"0":"post-544434","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-alzheimer","9":"tag-fr","10":"tag-france","11":"tag-health","12":"tag-neurologie","13":"tag-sante"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115575796851679268","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/544434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=544434"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/544434\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/544435"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=544434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=544434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=544434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}